ArticleJournal of medical biochemistry2026
Pramipexole enhances levodopa's therapeutic efficacy in Parkinson's disease: Role of glutaredoxin-1 (GRX1), peroxiredoxin3 (PRX3), thioredoxin (TRX), 8-hydroxy-2 -deoxyguanosine (8-OHDG), and neurosteroid dehydroepiandrosterone sulfate (DHEA-S).
Article in Journal of medical biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Parkinson's disease (PD) is characterised byprogressive neurodegeneration and dopamine deficiency.Levodopa remains a cornerstone treatment, but its longterm use is associated with motor complications andreduced efficacy. This study investigates the clinical benefits of combining pramipexole with Levodopa in PDpatients, focusing on improvements in oxidative stress,cognitive function, and motor control. Additionally, thestudy explores the role of novel biomarkers, includingglutaredoxin-1 (Grx1), peroxiredoxin-3 (Prx3), thioredoxin(Trx), 8-hydroxy-2'-deoxyguanosine (8-OHdG), and neurosteroid dehydroepiandrosterone sulfate (DHEA-S), inevaluating oxidative stress and neuroprotection. Methods: A total of 92 PD patients were enrolled andassigned to either a levodopa monotherapy group (n=46)or a pramipexole-levodopa combination group (n=46).Clinical efficacy was assessed using the Unified Parkinson'sDisease Rating Scale (UPDRS). Cognitive function wasevaluated using the Mini-Mental State Examination(MMSE) and the Montreal Cognitive Assessment (MoCA).Oxidative stress markers (SOD, GSH, GSH-PX, CAT, alongwith Grx1, Prx3, Trx, and 8-OHdG) were measured inserum samples. Additionally, DHEA-S was analysed as aneurosteroid biomarker to assess its potential role in cognitive and motor function improvements. Quality of life(QOL) was evaluated using the PDQ-39 questionnaire. Results: The combination therapy group exhibited a significantly higher effective rate (93.48% ) compared to the levodopa group (78.26% ) (P< 0.05). UPDRS scores were significantly lower in the combination group at 6- and12-week post-treatment (P < 0 .0 5 ). The combinationgroup also showed a significantly lower incidence ofadverse drug reactions (6.52% vs. 23.91% , P< 0.05). After3 months, the combination group displayed significantlyhigher levels of SOD, GSH, GSH-PX, CAT, Grx1, Prx3, andTrx, while 8-OHdG levels were significantly reduced, indicating enhanced neuroprotection and reduced oxidativestress. DHEA-S levels were also elevated, correlating withimproved MMSE and M oCA scores (P < 0 .0 5 ). Theobserved DHEA-S elevation in the combination group maybe due to pramipexole's dopaminergic modulation ofhypothalamic-pituitary-adrenal axis activity, potentiallyenhancing adrenal steroidogenesis. Alternatively, improvements in motor and cognitive function may reduce chronicstress, indirectly elevating DHEA-S. It suggests a neurosteroid-mediated cognitive benefit. QOL was significantlybetter in the combination group after 3 months of intervention (P< 0.05). Conclusions: Pramipexole combined with Levodopa significantly improves clinical outcomes, reduces adverse effects,enhances cognitive function, and alleviates oxidative stressin PD patients. The inclusion of novel biomarkers such asGrx1, Prx3, Trx, 8-OHdG, and DHEA-S provides deeperinsight into the molecular mechanisms underlying thesetherapeutic effects. This combination therapy represents avaluable strategy for improving PD management and warrants wider clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.